683 Capital Management, LLC Ardelyx, Inc. Transaction History

683 Capital Management, LLC

$1.1 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$3.29 - $6.64 $894,880 - $1.81 Million	272,000 New	272,000 $1.69 Million
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $127,500 - $292,500	250,000 Added 45.59%	798,405 $470,000
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $258,000 - $510,000	-300,000 Reduced 35.36%	548,405 $603,000
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $2.22 Million - $14.3 Million	-1,750,000 Reduced 67.35%	848,405 $1.12 Million
Q2 2021 Aug 16, 2021	SELL	$6.55 - $8.98 $1.32 Million - $1.8 Million	-200,902 Reduced 7.18%	2,598,405 $19.7 Million
Q1 2021 May 17, 2021	BUY	$6.1 - $7.69 $2.92 Million - $3.69 Million	479,307 Added 20.66%	2,799,307 $18.5 Million
Q4 2020 Feb 16, 2021	BUY	$5.05 - $7.1 $258,570 - $363,534	51,202 Added 2.26%	2,320,000 $15 Million
Q3 2020 Nov 16, 2020	BUY	$5.25 - $7.08 $601,723 - $811,467	114,614 Added 5.32%	2,268,798 $11.9 Million
Q1 2020 May 15, 2020	BUY	$4.35 - $8.79 $670,700 - $1.36 Million	154,184 Added 7.71%	2,154,184 $12.2 Million
Q4 2019 Feb 14, 2020	SELL	$4.23 - $8.29 $211,542 - $414,582	-50,010 Reduced 2.44%	2,000,000 $15 Million
Q3 2019 Nov 14, 2019	BUY	$2.15 - $6.28 $1.31 Million - $3.82 Million	607,664 Added 42.13%	2,050,010 $9.64 Million
Q2 2019 Aug 14, 2019	BUY	$2.49 - $3.73 $1.01 Million - $1.51 Million	405,942 Added 39.17%	1,442,346 $3.88 Million
Q1 2019 May 15, 2019	BUY	$1.88 - $3.35 $243,065 - $433,121	129,290 Added 14.25%	1,036,404 $2.9 Million
Q4 2018 Feb 14, 2019	BUY	$1.66 - $4.16 $426,809 - $1.07 Million	257,114 Added 39.56%	907,114 $1.62 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $2.41 Million - $3.77 Million	650,000 New	650,000 $2.41 Million

Others Institutions Holding ARDX

# of Institutions

219

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.

Account